Trial Profile
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jun 2019
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 18 Jun 2019 Status changed from completed to discontinued.
- 11 Dec 2018 A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies (DACO-018, DACO-017, DACO-020, DACO-016, E7373-A001-101, E7373-G000-202 and DACOGENAML2004 trial); results published in the Journal of Clinical Pharmacology
- 31 Jan 2018 Status changed from suspended to completed.